-
1
-
-
84886397930
-
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells
-
John LB, Devaud C, Duong CM, Yong C, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013;19:5636-46.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5636-5646
-
-
John, L.B.1
Devaud, C.2
Duong, C.M.3
Yong, C.4
Beavis, P.A.5
Haynes, N.M.6
-
2
-
-
84858758766
-
Adoptive immunotherapy for cancer: Harnessing the T cell response
-
Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12: 269-81.
-
(2012)
Nat Rev Immunol
, vol.12
, pp. 269-281
-
-
Restifo, N.P.1
Dudley, M.E.2
Rosenberg, S.A.3
-
3
-
-
79952187823
-
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
-
Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.
-
(2011)
Mol Ther
, vol.19
, pp. 620-626
-
-
Parkhurst, M.R.1
Yang, J.C.2
Langan, R.C.3
Dudley, M.E.4
Nathan, D.A.5
Feldman, S.A.6
-
4
-
-
84877669593
-
The basic principles of chimeric antigen receptor design
-
Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-98.
-
(2013)
Cancer Discov
, vol.3
, pp. 388-398
-
-
Sadelain, M.1
Brentjens, R.2
Riviere, I.3
-
5
-
-
80051775476
-
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
-
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
-
(2011)
Sci Transl Med
, vol.3
-
-
Kalos, M.1
Levine, B.L.2
Porter, D.L.3
Katz, S.4
Grupp, S.A.5
Bagg, A.6
-
6
-
-
84876325876
-
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
-
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
-
(2013)
N Engl J Med
, vol.368
, pp. 1509-1518
-
-
Grupp, S.A.1
Kalos, M.2
Barrett, D.3
Aplenc, R.4
Porter, D.L.5
Rheingold, S.R.6
-
7
-
-
77950475517
-
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
-
Morgan RA, Yang JC, Kitano M, Dudley ME, LaurencotCM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
-
(2010)
Mol Ther
, vol.18
, pp. 843-851
-
-
Morgan, R.A.1
Yang, J.C.2
Kitano, M.3
Dudley, M.E.4
Laurencot, C.M.5
Rosenberg, S.A.6
-
8
-
-
84874869077
-
Antagonist antibodies toPD-1andB7-H1 (PD-L1) inthe treatment of advancedhuman cancer
-
SznolM,ChenL. Antagonist antibodies toPD-1andB7-H1 (PD-L1) inthe treatment of advancedhuman cancer.ClinCancerRes 2013;19:1021-34.
-
(2013)
ClinCancerRes
, vol.19
, pp. 1021-1034
-
-
Sznol, M.1
Chen, L.2
-
9
-
-
84864324543
-
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
-
Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012;209:1201-17.
-
(2012)
J Exp Med
, vol.209
, pp. 1201-1217
-
-
Yokosuka, T.1
Takamatsu, M.2
Kobayashi-Imanishi, W.3
Hashimoto-Tane, A.4
Azuma, M.5
Saito, T.6
-
10
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
11
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
-
12
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
-
(2013)
N Engl J Med
, vol.369
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
-
13
-
-
84886410237
-
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model
-
Morales-Kastresana A, Fernandez de Sanmamed M, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013;19:5546-80
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5546-5580
-
-
Morales-Kastresana, A.1
Fernandez De Sanmamed, M.2
Rodriguez, I.3
Palazon, A.4
Martinez-Forero, I.5
Labiano, S.6
|